Technology

VUNO, Inc. Narrows Third-Quarter Operating Loss to 2 Billion… Cost-Cutting Efforts Show Results

Kim Seung-kwon
2026-11-16 16:47:02
[Edaily Reporter Kim Seung-kwon ] VUNO, Inc.(338220)has significantly reduced its third-quarter operating loss, signaling a path toward improved profitability. While the AI-based cardiac arrest prediction medical device “VUNO Med-DeepCARS” accounts for the majority of revenue, the electrocardiogram (ECG) monitor “HATIV” is emerging as a new growth driver.

According to the Financial Supervisory Service’s electronic disclosure system on the 16th, VUNO, Inc.’s consolidated revenue for the third quarter of this year totaled 5.67 billion won, with an operating loss of 1.97 billion won. Compared to the cumulative operating loss of 8.32 billion won in the first half of the year—which averaged 4.1 billion won per quarter—the loss has been reduced to less than half that amount. Operating expenses in the third quarter totaled 7.64 billion won, a 22% decrease from the same period last year (9.81 billion won), demonstrating the effects of cost efficiency measures.



Cumulative revenue for the first three quarters totaled 17.83 billion won. Of this, revenue from prognosis and predictive solutions—the segment to which DeepCAS belongs—amounted to 15.46 billion won, accounting for 86.7% of the total. While third-quarter revenue alone saw a slight decline to 5.7 billion won from 10.8 billion won a year earlier, the company views the increase in new revenue as encouraging.

The company is also expanding its overseas business footprint. In September, VUNO, Inc. signed a two-year exclusive sales agreement with Guorun, a Chinese medical technology company, for Hainan Province. In the Middle East, the company aims to obtain regulatory approval by the end of the year. Domestically, VUNO, Inc. is building clinical evidence through a cluster-randomized study involving 70,000 patients across four hospitals.

The company is also taking steps to strengthen its financial position. VUNO, Inc. is proceeding with a capital increase through a rights offering followed by a public offering of unsubscribed shares, totaling approximately 31.3 billion won. Of this amount, 20 billion won will be used to repay perpetual convertible bonds, while the remainder will be allocated as funding for overseas expansion, including U.S. Food and Drug Administration (FDA) approval and international sales operations. The detailed schedule will be finalized at a later date.

Lee Ye-ha, CEO of VUNO, Inc., stated, “Although DeepCARS revenue has been adjusted due to the impact of regulatory transition, HATIV is creating a new growth engine centered on industrial sites.”

Economy

Corporation

IT·Science

Economy

[Market Insight] Aju IB Holds Its Own in 3Q Despite KOSDAQ Correction… Accelerating Fund Formation Toward Year-End

AJU IB INVESTMENT CO., LTD.(027360)posted relatively solid earnings despite an unstable market environment marked by a correction in the KOSDAQ market and exchange rate fluctuations. Although valuatio…
2026-11-16 16:58:02

Corporation

'Balanced Growth in Fashion and Beauty' LF Reports 51.1 Billion Won in Q3 Operating Profit… Up 217%

LF achieved both revenue growth and improved profitability in the third quarter, driven by balanced growth across its in-house and imported fashion and beauty brands. LF(093050)According to the quarte…
2026-11-16 16:38:14

IT·Science

Boryung to Co-Market Celltrion Pharm Inc.’s Diabetes Drugs ‘Nesina’ and ‘Actos’… Secures 51.7 Billion Blockbuster Deal

Boryung(003850)and Celltrion Pharm Inc. will jointly market the “Nesina” and “Actos” product lines for the treatment of type 2 diabetes. The strategy is to expand their presence in the domestic diabet…
2026-11-16 16:58:03